Autres langues Medivir AB

Actions

MVIR B

SE0020181014

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:31 26/04/2024			Varia. 5j.	Varia. 1 janv.
3,24 ^SEK	+6,23 %		+21,35 %	+13,68 %

22/02	Medivir présente des données qui renforcent l'association Fostrox/Lenvima dans le cancer primitif du foie lors du sommet de l'Easl sur le cancer du foie	CI
15/02	Transcript : Medivir AB, Q4 2023 Earnings Call, Feb 15, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStock: Medivir optimizes study design after meeting FDA	26/04
Medivir Gets Two US FDA Designations for MIV-711	25/04
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	25/04
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	25/04
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue	23/04
BioStock: Medivir's partner makes clinical progress in veterinary project	19/04
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act	16/04
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701	15/04
BioStock: Medivir continues to accelerate development with fostrox	12/04
Medivir : The Nomination Committees proposal for the AGM	09/04
Medivir to present at Investing in Oncology Forum on April 10	09/04
Medivir : Corporate Governance Report	05/04
Medivir 2023 Annual Report published	04/04
Medivir : Notice of AGM 2024	04/04
Notice of Annual General Meeting of Medivir AB (publ)	04/04
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21/03
Medivir to present at Swiss Nordic Bio in Zürich on March 7	06/03
Medivir to present at the Life Science Day in Gothenburg on March 6	04/03
Change in Medivir's nomination committee before the 2024 AGM	26/02
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Medivir AB

Actions

MVIR B

SE0020181014

Autres langues

Filtres